Speedus Corp.: Zargis Medical Corp. to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference

STAMFORD, Conn., Nov. 13 /PRNewswire-FirstCall/ -- Speedus Corp. today announced that it will be releasing a free trial version of its Zargis Cardioscan software during the American Heart Association's 2009 Scientific Sessions conference, taking place this November 15-17 in Orlando. Zargis is exhibiting at the conference with 3M Littmann, the developers of the companion hardware -- the 3M Littmann Electronic Stethoscope Model 3200 -- which wirelessly transfers heart, lung and other body sounds to Zargis Cardioscan and Zargis StethAssist software for further analysis.

The annual American Heart Association's Scientific Sessions conference is the world's pre-eminent gathering of healthcare professionals devoted to understanding, treating, assessing, and preventing cardiovascular disease and stroke. The 2008 Scientific Sessions event was attended by more than 17,000 medical professionals.

About Zargis Cardioscan

Zargis Cardioscan is the first and only computer-assisted medical device designed to support physicians in analyzing heart sounds for the identification of suspected systolic and diastolic murmurs. Cardioscan is a non-invasive device that is easy to use, portable, and takes just minutes to perform. The device implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. Cardioscan provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. Cardioscan is intended to enhance auscultation a procedure that has been universally employed through a stethoscope for nearly two-hundred years.

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.

Speedus Corp.